Literature DB >> 10952777

BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.

H Yazici1, O Bitisik, E Akisik, N Cabioglu, P Saip, M Muslumanoglu, G Glendon, E Bengisu, S Ozbilen, M Dincer, S Turkmen, I L Andrulis, N Dalay, H Ozcelik.   

Abstract

To date, BRCA1 and BRCA2 mutations in breast and/or ovarian patients have not been characterized in the Turkish population. We investigated the presence of BRCA mutations in 53 individuals with a personal and family history of breast and/or ovarian cancer, and 52 individuals with a personal history of breast cancer diagnosed below age 50 without additional family history. We have identified 11 mutations (nine BRCA1 and two BRCA2) using combined techniques involving protein truncation test, direct sequencing and heteroduplex analysis. We found eight out of 53 patients (15.1%) with a family history to carry BRCA gene mutations (seven BRCA1 and one BRCA2). Of these, four were found in 43 families presenting only breast cancer histories, and four were found in families presenting ovarian cancer with or without breast cancer. We also demonstrated two BRCA1 and one BRCA2 mutations in three out of 52 (5.8%) early-onset breast cancer cases without additional family history. Three of nine BRCA1 and both BRCA2 mutations detected in this study were not reported previously. These mutations may be specific to the Turkish population. The BRCA1 5382insC mutation, specific to Ashkenazi and Russian populations, was found twice in our study group, representing a possible founder mutation in the Turkish population. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952777      PMCID: PMC2363542          DOI: 10.1054/bjoc.2000.1332

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.

Authors:  D Abeliovich; L Kaduri; I Lerer; N Weinberg; G Amir; M Sagi; J Zlotogora; N Heching; T Peretz
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

2.  Molecular and population genetic analyses of beta-thalassemia in Turkey.

Authors:  G O Tadmouri; S Tüzmen; H Ozçelik; A Ozer; S M Baig; E B Senga; A N Başak
Journal:  Am J Hematol       Date:  1998-03       Impact factor: 10.047

3.  A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.

Authors:  D B Berman; J Costalas; D C Schultz; G Grana; M Daly; A K Godwin
Journal:  Cancer Res       Date:  1996-08-01       Impact factor: 12.701

4.  Heteroduplex and protein truncation analysis of the BRCA1 185delAG mutation.

Authors:  H Ozcelik; Y J Antebi; D E Cole; I L Andrulis
Journal:  Hum Genet       Date:  1996-09       Impact factor: 4.132

5.  Population genetics of BRCA1 and BRCA2.

Authors:  C I Szabo; M C King
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

6.  Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia.

Authors:  S A Gayther; P Harrington; P Russell; G Kharkevich; R F Garkavtseva; B A Ponder
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

7.  Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients.

Authors:  H Ozçelik; B Schmocker; N Di Nicola; X H Shi; B Langer; M Moore; B R Taylor; S A Narod; G Darlington; I L Andrulis; S Gallinger; M Redston
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

8.  Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.

Authors:  E Levy-Lahad; R Catane; S Eisenberg; B Kaufman; G Hornreich; E Lishinsky; M Shohat; B L Weber; U Beller; A Lahad; D Halle
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

9.  Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.

Authors:  S Håkansson; O Johannsson; U Johansson; G Sellberg; N Loman; A M Gerdes; E Holmberg; N Dahl; N Pandis; U Kristoffersson; H Olsson; A Borg
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

10.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

View more
  13 in total

Review 1.  Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries.

Authors:  Ava Kwong; Vivian Y Shin; John C W Ho; Eunyoung Kang; Seigo Nakamura; Soo-Hwang Teo; Ann S G Lee; Jen-Hwei Sng; Ophira M Ginsburg; Allison W Kurian; Jeffrey N Weitzel; Man-Ting Siu; Fian B F Law; Tsun-Leung Chan; Steven A Narod; James M Ford; Edmond S K Ma; Sung-Won Kim
Journal:  J Med Genet       Date:  2015-07-17       Impact factor: 6.318

2.  Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population.

Authors:  Lucian Negura; Nancy Uhrhammer; Anca Negura; Vlad Artenie; Eugen Carasevici; Yves-Jean Bignon
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

Review 3.  Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Authors:  Murray Joseph Casey; Chhanda Bewtra
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

4.  Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry.

Authors:  Anna Marie Mulligan; Irene Raitman; Linda Feeley; Dushanthi Pinnaduwage; Linh T Nguyen; Frances P O'Malley; Pamela S Ohashi; Irene L Andrulis
Journal:  Clin Cancer Res       Date:  2012-12-04       Impact factor: 12.531

5.  Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia.

Authors:  Wafa Troudi; N Uhrhammer; C Sibille; C Dahan; W Mahfoudh; C Bouchlaka Souissi; T Jalabert; L Chouchane; Y J Bignon; F Ben Ayed; A Ben Ammar Elgaaied
Journal:  J Hum Genet       Date:  2007-10-09       Impact factor: 3.172

6.  Novel germline mutations in BRCA2 gene among 96 hereditary breast and breast-ovarian cancer families from Kerala, South India.

Authors:  Vani Syamala; Leelakumari Sreeja; Volga S Syamala; B Vinodkumar; Praveenkumar B Raveendran; Hariharan Sreedharan; Ratheesan Kuttappan; Lekshmi Balakrishnan; Ravindran Ankathil
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-15       Impact factor: 4.553

7.  Analysis of menstrual, reproductive, and life-style factors for breast cancer risk in Turkish women: a case-control study.

Authors:  Betul Oran; Ismail Celik; Mustafa Erman; Esmen Baltali; Nurullah Zengin; Figen Demirkazik; Sabahat Tezcan
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

8.  Prevalence of BRCA1 and BRCA2 Germline Mutations in Breast Cancer Women of Multiple Ethnic Region in Northwest China.

Authors:  Jianghua Ou; Tao Wu; Rolf Sijmons; Duo Ni; Wenting Xu; Halmurat Upur
Journal:  J Breast Cancer       Date:  2013-03-31       Impact factor: 3.588

9.  Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa? - a systematic review.

Authors:  Lawal Abdulrazzaq Oluwagbemiga; Atoyebi Oluwole; Adesunkanmi Abdulrasheed Kayode
Journal:  Springerplus       Date:  2012-12-28

10.  Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families.

Authors:  Mateja Krajc; Erik Teugels; Janez Zgajnar; Guido Goelen; Nikola Besic; Srdjan Novakovic; Marko Hocevar; Jacques De Grève
Journal:  BMC Med Genet       Date:  2008-09-10       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.